Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
News|Articles|July 22, 2014
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-08-06-2014
- Volume 10
- Issue 8
Novasep Passes FDA Inspections on Two Sites
Author(s)Pharmaceutical Technology Editors
Novasep gains approval from FDA to produce new molecular entity for US market.
Advertisement
The FDA inspections took place during June 2014 at Novasep’s Chasse-sur-Rhone and Pompey sites in France. The Chasse-sur-Rhone site is responsible for the synthesis of late stage intermediates and API, while the Pompey site takes charge of the last purification step.
Source:
Articles in this issue
about 12 years ago
Acute Need for Supply Chain Transparencyabout 12 years ago
Metrics Contract Services Adopts New Name and Logoabout 12 years ago
Steady Progress Toward Continuous Flow API Synthesisabout 12 years ago
When Payers Refuse to Cover New Drugs, CMOs Take a Hitabout 12 years ago
Catalent Issues Initial Public Offeringabout 12 years ago
Moving Toward a Safer Supply Chainabout 12 years ago
Hovione's API Facility in Cork, Ireland Passes FDA Inspectionabout 12 years ago
Croda Obtains EXCiPACT Certification for Mevisa Siteabout 12 years ago
SGS Life Science Services to Expand Shanghai FacilityAdvertisement
Related to this article
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Advertisement
Advertisement